Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the various roles of RANK signaling in bone remodeling, immune function, and epithelial differentiation, highlighting its potential involvement in cancer mechanisms; it reports no new clinical results.

In this study, researchers analyzed over 5,000 T cells per sample using scRNA+TCR-seq technology and found that dual TCR Tregs are present in high proportions across various mouse tissues, showing unique TCR pairing patterns, V(D)J usage, and mRNA expression compared to single TCR Tregs.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.

This review examines platelet-rich plasma for tissue repair and regeneration, reporting promising but inconclusive efficacy across applications; the authors stress the need for rigorous clinical trials.

This study found that BCG injection in COVID-19 convalescent adults reduced long COVID symptoms like hearing and cognitive issues but also led to increased hair loss in women at six months.

This study found that keratinocyte stem cells in mouse skin are closely related to side population or BCRP1-positive cells based on their localization and marker expression.

In this study, researchers found that RORA directly regulates the expression of the Bnip3 gene, which is crucial for hair follicle stem cell health, using rat HFSCs as a model. They propose that targeting RORA could modulate HFSC status.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

This case study of three siblings highlights the importance of recognizing dermatologic signs—alopecia and periorificial dermatitis—for early diagnosis and treatment of biotin-responsive multiple carboxylase deficiency.

In this study, Mononuclear Cells provided site-specific protection against chemotherapy-induced alopecia in rats treated with Ara-C, but not with CTX or VP-16, while PRP showed no protective effect.

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

This study found that most completely excised basal cell carcinomas in the head and neck were nodular, with a 2.7% recurrence rate, particularly in median areas, likely due to anatomical and histopathological factors.

This spotlight highlights the Brazilian Association of Hair Restoration Surgery and shares the positive experiences of the International Society of Hair Restoration Surgery members with their Brazilian colleagues, reporting no new findings.

This case report describes the successful treatment of Sarcoptes scabiei infestation in rabbits using Ivermectin, Vimeral syrup, and Benzyl Benzoate, resulting in the resolution of clinical signs and elimination of the parasite within four weeks.

A 5-year-old girl with a rare skin disorder was effectively treated with skin creams instead of oral medication.

Bhamrung-Lohit may help with inflammation and oxidation.

This review discusses the use of platelet-rich plasma for various dermatologic conditions but reports inconsistent evidence and a lack of standardized protocols; patients often report high satisfaction despite mixed clinical outcomes.

In this case study, drospirenone use masked the diagnosis of a rare form of congenital adrenal hyperplasia, suggesting a possible delay in detecting underlying endocrinopathies.

This article introduces a new Core Curriculum for Hair Restoration Surgery, aimed at enhancing physician competence in diagnosing and treating hair loss with a multidisciplinary approach.

In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.

This announcement from the American Board of Hair Restoration Surgery details the establishment of two oral examinations for 2024, with the first taking place at the Italian/European Congress in Milan, Italy, in May.

This study found that Prss53-mutated rabbits exhibited curved hair and skeletal dyskinesia, suggesting a link between Prss53 loss and these traits, potentially involving disrupted calcium metabolism.

This letter discusses how differentiating features in clinical and radiological findings can help distinguish pulmonary Langerhans cell histiocytosis and Birt-Hogg-Dube syndrome from lymphangioleiomyomatosis, noting overlapping symptoms but specific distinctive traits.

This study describes the development of a monoclonal antibody, 005-C04, which blocks PRLR-mediated signaling, suggesting its potential for furthering understanding of PRLR's role in health and disease.

This article discusses the paradoxical effects of valproic acid on hair, reporting both drug-induced hair loss and the potential for hair growth when used topically, but presents no original research findings.

This study found that 4-(ethoxycarbophenyl) retinamide (RI) exhibited significantly lower acute, subacute, and chronic toxicity compared to other retinoids in mouse and rat models.

This case report describes chronic iron deficiency anemia in a patient with Cronkhite-Canada syndrome, highlighting the need for more data to guide treatment and cancer surveillance due to its rarity and mortality risk.

The conclusion is that improved training and oversight for cosmetic procedures are recommended to better protect patients.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.